SASandra Andorf

Sandra Andorf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra Andorf has a total of 330 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A semi-automated tool for improving Assessments and Lab Tests data annotation in ImmPort

    by Amanda R. Tursi, Joshua D. Fortriede, Kevin Burns, Nicholas K. Saba, Parisa Pirani, Matthew D. Strub, Patrick Dunn, Henry Schaefer, Sandra Andorf

    Public data sharing in immunological and clinical research is essential for transparency, reproducibility, and secondary analysis. However, many datasets in repositories such as ImmPort lack sufficient structured data to enable reuse. ImmPort’s Assessments and Lab Tests templates — which capture critical clinical information — are often incomplete or omitted due to their complexity and the manual effort required. To address this challenge, an application with a graphical user interface requiring no programming was developed to facilitate population of these templates. The tool streamlines the submission process by reducing time and complexity for data contributors while ensuring template formatting. It integrates ImmPort files, study-specific data files, and a curated data dictionary to automate the mapping of study variables to the required fields within each template. The tool was evaluated on seven ImmPort studies with diverse designs. It successfully generated submission-ready templates that passed ImmPort’s internal validation and will be incorporated into the repository. By improving the feasibility and completeness of templates, this approach enhances the quality, findability, and reusability of data within ImmPort.

  • Open Access

    CytoBatchFlagR : A Comprehensive Framework to Objectively Assess High‐Parameter Cytometry Data for Batch Effects

    by Shruti Eswar, Zachary T. Koenig, Amanda R. Tursi, José Cobeña‐Reyes, Tamara Tilburgs, Sandra Andorf

    Rapid advancements in mass and flow cytometry technologies have allowed researchers to generate and analyze high‐dimensional single cell datasets, often utilizing upwards of 40 protein markers. Such high‐parameter cytometry is increasingly used in longitudinal immunological studies, but technical variations across experimental batch runs can confound biological signals. To mitigate the impact on downstream analyses, many studies include reference control samples in every run, and several approaches exist to adjust for batch effects. However, tools that objectively identify problematic batches and markers present within a dataset are limited. We introduce CytoBatchFlagR, a comprehensive and interpretable tool designed to flag batch‐related problems at the marker and cell cluster level based on robust statistical evaluations. Batch and marker variations are assessed based on median signal intensities of negative and positive cell populations and positive cell frequencies, along with Earth Mover's Distance (EMD) of signal intensity distributions. Additionally, CytoBatchFlagR identifies cell type specific batch problems via unsupervised clustering. The tool is suitable for mass and flow cytometry datasets where it objectively detects distinct types of batch issues. We developed and tested CytoBatchFlagR using three cytometry datasets to demonstrate its utility and performance. We also demonstrated CytoBatchFlagR's effectiveness in assessing datasets that include or lack reference controls. CytoBatchFlagR improves quality control by enabling objective identification of technical variations that may impact downstream analysis in high‐parameter cytometry data. The tool uses a series of complementary metrics to identify potential batch‐related problems at the marker and cell population level and presents the results through interpretable visualizations. This allows users to make informed decisions about whether to apply batch correction or exclude specific batches or markers from downstream analyses. CytoBatchFlagR is freely available as R scripts, with documentation and a tutorial to help users get started.


  • Open Access

    B‐Cell Repertoire of Children With Atopic Dermatitis Exhibits Altered IgE Maturation Associated With Allergic Food Sensitization

    by Kirandeep K. Gill, Carolina Moore, Onyekachi Nwogu, John W. Kroner, Wan‐Chi Chang, Jeffrey Burkle, Samuel J. Virolainen, Mariana L. Stevens, Asel Baatyrbek, Emily R. Miraldi, et al.

    IgE B cells produce antibodies responsible for the inappropriate specificity seen in allergic disease. In this study, we sequence antibody gene repertoires from a large, well‐characterized early life cohort at risk for developing food allergy. We found that food allergen sensitization was associated with lower IgE mutation frequencies that was abrogated in children living with a pet dog, suggesting potential molecular mechanisms underlying the hygiene hypothesis (i.e., protective effects of pet ownership and non‐antiseptic environs reported for allergic disease). We also observed increased IgE diversity and increased isotype‐switching to IgE, suggesting that B‐cell development is altered in those with food allergen sensitizations relative to those without. IgE diversity was even more extreme in subjects who were highly likely to be peanut allergic. Unlike food sensitization, we detected no effect of aeroallergen sensitization on IgE mutation levels and diversity. Consistent patterns of antibody rearrangement were associated with food allergen sensitization. These results have important implications for the allergic response driven by mast cells and basophils and the underlying drivers of the atopic march.


  • Open Access

    cytoFlagR: A comprehensive framework to objectively assess high-parameter cytometry data for batch effects

    by Shruti Eswar, Zachary T. Koenig, Amanda R. Tursi, José Cobeña-Reyes, Tamara Tilburgs, Sandra Andorf

    Motivation: High-parameter cytometry is widely used in longitudinal studies, but technical variation across batches can confound biological signals. However, tools that objectively identify problematic batches and markers are limited. Results: We introduce cytoFlagR, a comprehensive tool to flag batch-related problems at the marker and cell cluster level based on robust statistical evaluations. Batch and marker variations are assessed based on median signal intensities of negative and positive cell populations and positive cell frequencies, along with Earth Mover’s Distance (EMD) of signal intensity distributions. Additionally, cytoFlagR identifies cell type specific batch problems via unsupervised clustering and is suitable for mass and spectral cytometry datasets where it objectively detects distinct types of batch issues. We demonstrated cytoFlagR’s utility for assessing datasets that include or lack reference controls. Thus, cytoFlagR improves quality control by objective identification of technical variations that may impact downstream analysis. Availability and Implementation: cytoFlagR is freely available as R scripts with documentation and an example at https://github.com/AndorfLab/cytoFlagR . Contact: andorfsa@ucmail.uc.edu

  • Open Access

    CytoPheno: Automated descriptive cell type naming in flow and mass cytometry

    by Amanda R. Tursi, Celine S. Lages, Kenneth Quayle, Zachary T. Koenig, Rashi Loni, Shruti Eswar, José Cobeña-Reyes, Sherry Thornton, Tamara Tilburgs, Sandra Andorf

    Advances in cytometry have led to increases in the number of cellular markers that are routinely measured. The resulting complexity of the data has prompted a shift from manual to automated analysis methods. Currently, numerous unsupervised methods are available to cluster cells based on marker expression values. However, phenotyping the resulting clusters is typically not part of the automated process. Manually identifying both marker definitions (e.g. CD4 + , CCR7 + , CD45RA + , CD19 - ) and descriptive cell type names (e.g. naïve CD4 + T cells) based on marker expression values can be time-consuming, subjective, and error-prone. In this work we propose an algorithm that addresses these problems through the creation of an automated tool, CytoPheno, that assigns marker definitions and cell type names to unidentified clusters. First, post-clustered expression data undergoes per-marker calculations to assign markers as positive or negative. Next, marker names undergo a standardization process to match to Protein Ontology identifier terms. Finally, marker descriptions are matched to cell type names within the Cell Ontology. Each part of the tool was tested with benchmark data to demonstrate performance. Additionally, the tool is encompassed in a graphical user interface (R Shiny) to increase user accessibility and interpretability. Overall, CytoPheno can aid researchers in timely and unbiased phenotyping of post-clustered cytometry data.


  • Open Access

    Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease‐Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta‐Analysis of Randomized Controlled Trials

    by Yuxiang Li, Bin Huang, Sandra Andorf, Xiaomeng Yue, Daniel J. Lovell, Hermine I. Brunner

    Objective: We evaluated the efficacy and safety profiles of JAK inhibitors (JAKi) and biologic disease‐modifying antirheumatic drugs (bDMARDs) when used with or without methotrexate (MTX) for the treatment of nonsystemic forms of juvenile idiopathic arthritis (nsJIA).Methods: Randomized clinical trials (RCTs) investigating efficacy and safety outcomes of JAKi or bDMARDs for the nsJIA population up to 2023 were searched in ClinicalTrial.gov, PubMed, EMBASE, and Cochrane databases. Bayesian arm‐based network meta‐analysis compared efficacy as measured by Juvenile Idiopathic Arthritis‐American College of Rheumatology 70 (JIA‐ACR70) improvement and safety based on rates of serious adverse events (SAEs) among all therapies.Results: Eligible studies included 45 citations from 16 RCTs (7 parallel and 9 withdrawal trials) with a total of 1,821 participants that investigated nine bDMARDs, three with and six without MTX co‐treatment, and two JAKis (tofacitinib and baricitnib). The reported SAE incidence rates ranged from 0 to 0.3 per person‐year of follow‐up; none of the pairwise comparisons were statistically significant. The JIA‐ACR70 improvement by 16 weeks of treatment ranged from 11.3% to 89.5%. Compared with controls, significant JIA‐ACR70 improvements were observed for etanercept, golimumab, and all three combination therapies (adalimumab+MTX, etanercept+MTX, and infliximab+MTX), with odds ratios ranging from 2.97 to 3.99. No significant pairwise comparisons between bDMARDs and JAKi versus bDMARDs were noted.Conclusion: Overall, no significant evidence was found for efficacy and safety profiles in pairwise comparisons of JAKis and bDMARDs. Future studies will expand the meta‐analysis by including non‐RCT studies and individual participant data. image


  • Open Access

    Use of Antibody Structural Information in Disease Prediction Models Reveals Antigen Specific B Cell Receptor Sequences in Bulk Repertoire Data

    by Onyekachi Nwogu, Kirandeep K. Gill, Carolina Moore, John W. Kroner, Wan-Chi Chang, Jeffrey Burkle, Mariana L. Stevens, Asel Baatyrbek Kyzy, Emily R. Miraldi, Jocelyn M. Biagini, et al.

    Convergent antibodies are highly similar antibodies elicited in multiple individuals in response to the same antigen. Convergent antibodies provide insight into shared immunological responses and show great promise as diagnostic biomarkers. They have typically been identified using methods that consider the amino acid sequence of the third complementarity-determining region (CDR3) of immunoglobulin heavy chain (IgH). In this study, we extend this definition of convergent antibodies to use structural information about the three IgH CDR regions (CDR1-3) and antibody isotype. We measure the performance of both definitions of convergence by their ability to predict disease status from bulk IgH sequencing data for two different disease cohorts: HIV infection and food allergen sensitization. We show that using predicted structural information outperforms prior approaches for the prediction of food sensitization status and performs on par for HIV infection status. Additionally, the use of structural information and antibody isotype enables better model interpretation and more immunological insights. The structurally convergent antibody groups driving HIV prediction accuracy are from known HIV-binding antibodies expressing the appropriate isotype. Thus, the incorporation of structural information can enable the identification of antigen specific antibody groups from bulk IgH sequencing data.

  • Progressive accumulation of hyperinflammatory NKG2D low NK cells in early childhood severe atopic dermatitis

    by David E. Ochayon, Stanley B. DeVore, Wan-Chi Chang, Durga Krishnamurthy, Harsha Seelamneni, Brittany Grashel, Daniel Spagna, Sandra Andorf, Lisa J. Martin, Jocelyn M. Biagini, et al.

    Atopic dermatitis (AD) is a chronic inflammatory skin disease that often precedes the development of food allergy, asthma, and allergic rhinitis. The prevailing paradigm holds that a reduced frequency and function of natural killer (NK) cell contributes to AD pathogenesis, yet the underlying mechanisms and contributions of NK cells to allergic comorbidities remain ill-defined. Here, analysis of circulating NK cells in a longitudinal early life cohort of children with AD revealed a progressive accumulation of NK cells with low expression of the activating receptor NKG2D, which was linked to more severe AD and sensitivity to allergens. This was most notable in children co-sensitized to food and aeroallergens, a risk factor for development of asthma. Individual-level longitudinal analysis in a subset of children revealed coincident reduction of NKG2D on NK cells with acquired or persistent sensitization, and this was associated with impaired skin barrier function assessed by transepidermal water loss. Low expression of NKG2D on NK cells was paradoxically associated with depressed cytolytic function but exaggerated release of the proinflammatory cytokine tumor necrosis factor–α. These observations provide important insights into a potential mechanism underlying the development of allergic comorbidity in early life in children with AD, which involves altered NK cell functional responses, and define an endotype of severe AD.


  • Open Access

    Immune cell profiles associated with human exposure to perfluorinated compounds (PFAS) suggest changes in natural killer, T helper, and T cytotoxic cell subpopulations

    by Amanda R. Tursi, Birgitte Lindeman, Anja Bråthen Kristoffersen, Hege Hjertholm, Eugenia Bronder, Monica Andreassen, Trine Husøy, Hubert Dirven, Sandra Andorf, Unni C. Nygaard


  • Open Access

    Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making

    by Yuxiang Li, Ashley Devonshire, Bin Huang, Sandra Andorf

    Background: The Learning Early About Peanut Allergy (LEAP) trial showed that early dietary introduction of peanut reduced the risk of developing peanut allergy by age 60 months in infants at high risk for peanut allergy. In this secondary analysis of LEAP data, we aimed to determine risk subgroups within these infants and estimate their respective intervention effects of early peanut introduction.Methods: LEAP raw data were retrieved from ITNTrialShare.org. Conditional random forest was applied to participants in the peanut avoidance arm to select statistically important features for the classification and regression tree (CART) analysis to group infants based on their risk of peanut allergy at 60 months of age. Intervention effects were estimated for each derived risk subgroup using data from both arms. Our main model was generated based on baseline data when the participants were 4–11 months old. Specific IgE measurements were truncated to account for the limit of detection commonly used by laboratories in clinical practice.Results: The model found infants with higher predicted probability of peanut allergy at 60 months of age had a similar relative risk reduction, but a greater absolute risk reduction in peanut allergy with early introduction of peanut, than those with lower probability. The intervention effects were significant across all risk subgroups. Participants with baseline peanut sIgE ≥0.22 kU/L (n = 78) had an absolute risk reduction of 40.4% (95% CI 27.3, 51.9) whereas participants with baseline peanut sIgEn = 226) had an absolute risk reduction of 6.5% (95% CI 2.6, 11.0). These findings were consistent in sensitivity analyses using alternative models.Conclusion: In this study, risk subgroups were determined among infants from the LEAP trial based on the probability of developing peanut allergy and the intervention effects of early peanut introduction were estimated. This may be relevant for further risk assessment and personalized clinical decision‐making.